Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

Blood (2024) 143 (13): 1231–1241.

https://doi.org/10.1182/blood.2023022204

Published: 2024

Includes: Supplemental data

Journal Articles

Access offsets poverty in quest for CAR T cells

Rayne H. Rouce, Eneida Nemecek

Blood (2023) 141 (6): 558–560.

https://doi.org/10.1182/blood.2022018552

Published: 2023

Journal Articles

Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following CAR-T Therapy

Jay A. Read, Feiyan Mo, Maksim Mamonkin, Rayne H. Rouce, Katherine Y. King

Blood (2022) 140 (Supplement 1): 10271–10272.

https://doi.org/10.1182/blood-2022-159579

Published: 2022

Journal Articles

CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma

Blood (2022) 140 (Supplement 1): 412–414.

https://doi.org/10.1182/blood-2022-160244

Published: 2022

Journal Articles

Reverse translational studies inform dual-targeted CAR T-cell design

Rayne H. Rouce, Lauren Scherer

Blood (2022) 140 (5): 409–410.

https://doi.org/10.1182/blood.2022016928

Published: 2022

Journal Articles

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Blood (2022) 140 (1): 16–24.

https://doi.org/10.1182/blood.2022015728

Published: 2022

Journal Articles

Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Samuel John, Michael A. Pulsipher, Amy Moskop, Zhen-Huan Hu, Christine L. Phillips, Erin Marie Hall, Steven P. Margossian, Sarah Nikiforow, Paul L. Martin, Benjamin Oshrine, Amy K. Keating, Rayne H. Rouce, Ranjan Tiwari, Santiago Redondo, Jennifer Willert, Abhijit Agarwal, Marcelo C Pasquini, Stephan A. Grupp

Blood (2021) 138 (Supplement 1): 428.

https://doi.org/10.1182/blood-2021-146393

Published: 2021

Journal Articles

Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

Blood (2021) 138 (Supplement 1): 1763.

https://doi.org/10.1182/blood-2021-153421

Published: 2021

Journal Articles

Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma

Rayne H. Rouce, LaQuisa C. Hill, Tyler S. Smith, Lina Yang, Blakely Boriskie, Madhuwanti Srinivasan, Huimin Zhang, Silvana Perconti, Birju Mehta, Olga Dakhova, Bambi J. Grilley, Helen E. Heslop, Malcolm K. Brenner, Maksim Mamonkin

Blood (2021) 138 (Supplement 1): 654.

https://doi.org/10.1182/blood-2021-154142

Published: 2021

Journal Articles

A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

David H. Quach, PhD, Haran R. Ganesh, BS, Sachin Thakkar, PhD, Luis Becerra-Dominguez, BS, Birju Mehta, MS, Silvana Perconti, MS, Eric Anderson, BS, Emily M. Hsieh, MD, Olga Dakhova, MD, Huimin Zhang, BS, Bambi J. Grilley, RPh, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MD DSc, Carlos A. Ramos, MD, Rayne H. Rouce, MD, Natalia Lapteva, PhD, Cliona M. Rooney, PhD

Blood (2020) 136 (Supplement 1): 16.

https://doi.org/10.1182/blood-2020-141491

Published: 2020

Journal Articles

The earlier the better: timely mitigation of CRS

Rayne H. Rouce

Blood (2019) 134 (24): 2119–2120.

https://doi.org/10.1182/blood.2019003618

Published: 2019

Journal Articles

Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies

LaQuisa C. Hill, MD, Rayne H. Rouce, MD, Tyler S. Smith, Lina Yang, PhD, Madhuwanti Srinivasan, Huimin Zhang, BS, Silvana Perconti, Birju Mehta, MS, BS, Olga Dakhova, Josalind Randall, Bambi J. Grilley, RPh, Helen E. Heslop, MD DSc, Malcolm K. Brenner, MD PhD, Maksim Mamonkin, PhD

Blood (2019) 134 (Supplement_1): 199.

https://doi.org/10.1182/blood-2019-129559

Published: 2019

Journal Articles

Genomic Characterization of a Pediatric Cohort with Non-Malignant Lymphoproliferative Disorders

Blood (2019) 134 (Supplement_1): 83.

https://doi.org/10.1182/blood-2019-131884

Published: 2019

Journal Articles

CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies

Diogo Gomes-Silva, Madhuwanti Srinivasan, Sandhya Sharma, Ciaran M. Lee, Dimitrios L. Wagner, Timothy H. Davis, Rayne H. Rouce, Gang Bao, Malcolm K. Brenner, Maksim Mamonkin

Blood (2017) 130 (3): 285–296.

https://doi.org/10.1182/blood-2017-01-761320

Published: 2017

Includes: Supplemental data

Journal Articles

Equal opportunity CAR T cells

Rayne H. Rouce, Helen E. Heslop

Blood (2017) 129 (25): 3275–3277.

https://doi.org/10.1182/blood-2017-04-779983

Published: 2017

Journal Articles

Rapidly-Generated EBV-Specific T Cells (EBVST-cells) to Treat Type 2 Latency Lymphoma

Rayne H. Rouce, MD, Birju Mehta, Sandhya Sharma, Serena Kimi Perna, MD, Benjamin Shin, Vicky Torrano, Fnu Spoorthi, Natalia Lapteva, PhD, Catherine M. Bollard, MD, Adrian P. Gee, PhD, Carlos A. Ramos, MD, Shannon Inman, Karen L. Hodgkin, Kurt C. Gunter, MD, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MD, Cliona M. Rooney, PhD

Blood (2016) 128 (22): 2990.

https://doi.org/10.1182/blood.V128.22.2990.2990

Published: 2016

Journal Articles

Safety of Multiple Doses of CAR T Cells

Rayne H. Rouce, MD, Kristen Fousek, Nabil Ahmed, MD, Stephen Gottschalk, MD, Barbara Savoldo, MD, Gianpietro Dotti, MD, Carlos A. Ramos, MD, Chrystal Louis, MD, Cliona M. Rooney, PhD, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MD

Blood (2015) 126 (23): 4425.

https://doi.org/10.1182/blood.V126.23.4425.4425

Published: 2015

Journal Articles

A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignancies

Maksim Mamonkin, Rayne H. Rouce, Haruko Tashiro, Malcolm K. Brenner

Blood (2015) 126 (8): 983–992.

https://doi.org/10.1182/blood-2015-02-629527

Published: 2015

Includes: Supplemental data

Journal Articles

Natural Killer Cells In Pediatric Acute Lymphoblastic Leukemia Patients At Diagnosis Demonstrate An Inhibitory Phenotype and Reduced Cytolytic Capacity

Rayne H. Rouce, MD, Takuya Sekine, Gerrit Weber, MD, Claude Chew, Katayoun Rezvani, M.D., PhD, Catherine M. Bollard, MD, FRACP, FRCPA, Karen R Rabin, MD, PhD

Blood (2013) 122 (21): 1397.

https://doi.org/10.1182/blood.V122.21.1397.1397

Published: 2013

NARROW

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

Access offsets poverty in quest for CAR T cells

Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following CAR-T Therapy

CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma

Reverse translational studies inform dual-targeted CAR T-cell design

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma

A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

The earlier the better: timely mitigation of CRS

Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies

Genomic Characterization of a Pediatric Cohort with Non-Malignant Lymphoproliferative Disorders

CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies

Equal opportunity CAR T cells

Rapidly-Generated EBV-Specific T Cells (EBVST-cells) to Treat Type 2 Latency Lymphoma

Safety of Multiple Doses of CAR T Cells

A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignancies

Natural Killer Cells In Pediatric Acute Lymphoblastic Leukemia Patients At Diagnosis Demonstrate An Inhibitory Phenotype and Reduced Cytolytic Capacity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only